Crescita Therapeutics Inc.
CTX.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.90% | 20.53% | -223.47% | -130.08% | -112.71% |
| Total Depreciation and Amortization | -6.42% | -18.61% | -20.39% | 2.99% | 0.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -67.78% | 96.65% | -72.92% | -140.87% | 151.42% |
| Change in Net Operating Assets | 259.51% | 3.83% | 431.46% | -62.06% | 80.18% |
| Cash from Operations | 612.51% | 233.58% | 562.85% | -82.20% | 88.25% |
| Capital Expenditure | -226.68% | -2,818.66% | -- | -- | -704.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -226.68% | -2,544.98% | -- | -- | -41.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.62% | -6.80% | -8.91% | -9.09% | -6.06% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 49.67% | 51.25% | -- | -- | -112.50% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 9.60% | 31.13% | -53.59% | -139.07% | -16.46% |
| Foreign Exchange rate Adjustments | 521.59% | -176.22% | 113.43% | -18.92% | -218.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 227.59% | -175.39% | -939.18% | -92.81% | 74.62% |